GPT and Dysphonia: Among the total number of TRAEs reported, the most common sitravatinib-related AEs were gastrointestinal disorders (26%), dysphonia (16%) and alanine transaminase (ALT)/asparte transaminase (AST) increase (13%); whereas the most common sitravatinib and nivolumab-related AEs were fatigue (27%) and anorexia (27%) (table 2).